Clinical trials: Inflammatory Disorder
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
DeQuervains Tenosynovitis, Lateral Epicondylitis
Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders
The primary objective of this study is to compare local corticosteroid hand and elbow injections to placebo or ketorolac to determine if there is an equal or better reduction of symptoms for common orthopaedic upper extremity…
- Conditions
- DeQuervains Tenosynovitis, Lateral Epicondylitis, Tennis Elbow, Trigger Finger
- Trial name
- NCT02266433
- Testing
- Ketorolac, Dexamethasone
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- NYU Langone Health
Papulopustular Rosacea
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.
- Trial name
- NCT01872715
- Testing
- Oracea
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Galderma R&D
Colitis, Ulcerative
Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)
This study will be performed to compare the efficacy and safety of the classical "Step-Up" approach for treatment of moderate-to-severe active ulcerative colitis using oral prednisolone + oral 5-aminosalicylic acid (5-ASA) or…
- Trial name
- MUNIX (NCT00984568)
- Testing
- Infliximab, Prednisolone, 5-aminosalicylic acid
- Volunteers
- 28 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
A Study To Monitor Long-Term Treatment With PF-00547659
This study provides open-label drug to eligible patients who have completed a prior study of PF-00547659. The primary endpoint for this study is long-term safety.
- Trial name
- OPERA II (NCT01298492)
- Testing
- PF-00547659
- Where
- 112 sites in United States, Austria and 13 more
- Volunteers
- 268 people
- Sponsor
- Shire
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery.
- Conditions
- Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT02658812
- Testing
- Laboratory Biomarker Analysis, Talimogene Laherparepvec
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Septic Shock, Hypotension
Esmolol to Treat the Hemodynamic Effects of Septic Shock
The main purpose of this study is to determine the effects of controlling the heart rate of patients with septic shock using an intravenous medication called esmolol.
- Conditions
- Septic Shock, Hypotension, Tachycardia
- Trial name
- NCT02369900
- Testing
- Esmolol, Saline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Inclusion Body Myositis
A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
- Trial name
- NCT05721573
- Testing
- ABC008
- Where
- 45 sites in United States, Australia and 5 more
- Volunteers
- 272 people
- Sponsor
- Abcuro, Inc.
Crohn Disease
A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
The purpose of this study to examine the safety and efficacy of OPC-6535 and determine its optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic…
- Trial name
- NCT00317369
- Testing
- OPC-6535(Tetomilast)
- Where
- 8 sites in Japan
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Trial name
- NCT02855359
- Testing
- denintuzumab mafodotin, rituximab, cyclophosphamide
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- Seagen Inc.
ALK-activated Tumors
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor activity and characterize single and multiple-dose…
- Trial name
- NCT01742286
- Testing
- Ceritinib
- Where
- 23 sites in United States, Australia and 8 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
HIV, Inflammation
PET/CT Imaging Companion Study To ACTG A5314
HIV-infected individuals on antiretroviral therapy (ART) are at increased risk for cardiovascular disease (CVD), likely due to chronically increased inflammation.
- Conditions
- HIV, Inflammation, Atherosclerosis
- Trial name
- PET/CTMTX (NCT02312219)
- Testing
- Folic Acid, Low Dose Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
TKI258 for Metastatic Inflammatory Breast Cancer Patients
The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT01262027
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Crohn's Disease
Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension.
- Trial name
- NCT02405442
- Testing
- Andecaliximab
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 187 people
- Sponsor
- Gilead Sciences
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Crohn's Disease
CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
This is Phase 3, Randomized, Placebo-controlled study to demonstrate superiority of CT-P13 SC over Placebo SC in Patients With Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03945019
- Testing
- CT-P13 SC (Infliximab)
- Where
- 29 sites in United States, Belarus and 24 more
- Volunteers
- 396 people
- Sponsor
- Celltrion
Hidradenitis Suppurativa
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens…
- Trial name
- NCT04179175
- Testing
- secukinumab
- Where
- 191 sites in United States, Argentina and 36 more
- Volunteers
- 702 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease, Ulcerative Colitis
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Trial name
- NCT03884439
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 428 people
- Sponsor
- Pfizer
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.